Clinical Trial Update: A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase III study evaluating the pharmacodynamic effects and tolerability of Grazax for grass pollen allergy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Grass Pollen Allergy

Drugs mentioned

• GRAZAX (birch pollen sublingual immunotherapy tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Grass Pollen Allergy | Phase 3 | Status: COMPLETED